<DOC>
	<DOCNO>NCT00440037</DOCNO>
	<brief_summary>The purpose study assess safety efficacy long term dose AMG 531 thrombocytopenic Japanese subject ITP . It anticipate AMG 531 safe well tolerate long term treatment AMG 531 effectively raise maintain platelet count desire therapeutic range , individual dose adjustment base platelet count permit . This study available subject complete previous AMG 531 ITP study Japan meet eligibility criterion study .</brief_summary>
	<brief_title>Open Label Extension Study AMG 531 Japanese Subjects With ITP</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<criteria>Inclusion Criteria Subjects must previously complete AMG 531 ITP study Japan . Platelet count take screen visit must &lt; 50 x 109/L . Before studyspecific procedure , appropriate write informed consent must obtain . Exclusion Criteria Any significant change medical history since completion previous AMG 531 ITP study include bone marrow stem cell disorder new active malignancy know positive result test neutralizing antibody AMG 531 previous AMG 531 ITP study Currently receive treatment ITP except oral corticosteroid , azathioprine and/or danazol administer constant dose schedule least 4 week prior screen visit receive intravenous immunoglobulin , antiD immunoglobulin , drug administer increase platelet count ( eg , immunosuppressant etc ) within 1 week screen visit receive antimalignancy agent ( eg , cyclophosphamide , 6mercaptopurine , vincristine , vinblastine , Interferonalfa etc ) within 4 week screen visit receive monoclonal antibody drug ( eg , rituximab etc ) within 8 week screen visit Less 4 week since receipt therapeutic drug device Ministry Health , Labor Welfare ( MHLW ) approve indication screen visit ( exclude AMG 531 ) Pregnant breast feeding Subjects reproductive potential use adequate contraceptive precaution , judgment investigator know severe drug hypersensitivity Concerns subject 's compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>AMG 531</keyword>
	<keyword>ITP</keyword>
	<keyword>Long term treatment</keyword>
	<keyword>Japanese</keyword>
	<keyword>Romiplostim</keyword>
</DOC>